Provectus Biopharmaceuticals Inc (PVCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Sales | 0 | 0 | 0 | 58 | 279 |
| Gross Profit | N/A | N/A | N/A | 58 | 279 |
| Operating Expenses | 1,248 | 1,121 | 1,276 | 1,858 | 1,377 |
| Operating Income | -1,248 | -1,121 | -1,276 | -1,801 | -1,098 |
| Interest Expense | 53 | 47 | 48 | 51 | 64 |
| Pre-tax Income | -1,301 | -1,168 | -1,324 | -1,852 | -1,162 |
| Net Income Continuous | -1,301 | -1,168 | -1,324 | -1,852 | -1,162 |
| Minority Interests | -11 | -3 | -12 | -38 | -22 |
| Net Income | $-1,291 | $-1,165 | $-1,311 | $-1,814 | $-1,140 |
| EBITDA(a) | $-1,247 | $-1,120 | $-1,275 | $-1,800 | $-1,098 |